Exchange: OTC·Updated 03:59 PM EDT

RHHBYRoche Holdings AG ADR

$49.74
$1.32
(2.58%)
Today
EarningsJul 23
Mkt Cap$274.14B
Vol1.47M
65

Bullish Sentiment

How do you feel about RHHBY?

News
all
press releases
FDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCL
FDA accepts RHHBY filing for Lunsumio VELO plus Polivy in relapsed or refractory LBCL as a potential chemotherapy-free treatment option.
Zacks
News Placeholder
More News
News Placeholder
JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study
Jazz Pharmaceuticals' Zepzelca fails a phase III lung cancer study, but strong first-line uptake and 2026 guidance remain unchanged.
Zacks
News Placeholder
Novartis Reports Positive Data for Neuromuscular Disorder Drug
NVS announces positive FORTITUDE data as del-brax met key endpoints, supporting its potential as a disease-modifying treatment for FSHD.
Zacks
News Placeholder
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
PBYI's shares rally 19% in three months as rising Nerlynx demand and a raised 2026 revenue outlook boost investor confidence.
Zacks
News Placeholder
Roche's Tecentriq Plus Chemo Gets FDA Priority Tag for Colon Cancer
RHHBY wins FDA priority review for Tecentriq plus FOLFOX6 in stage III dMMR/MSI-H colon cancer, with a decision due in October 2026.
Zacks
News Placeholder
The $100 Billion Oncology Opportunity Investors are Starting to Notice
Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the race to develop more effective treatments for some of the deadliest forms of cancer. From precision oncology and targeted therapies to next-generation approaches designed to overcome treatment resistance, a new wave of innovation is emerging that could reshape cancer care over the next decade. $NTHI, $GSK, $NUVL, $PFE, $RHHBY, $BMY
24-7 Market News
News Placeholder
The Zacks Analyst Blog Highlights Amazon.com, Bank of America, Roche, Oak Valley Bancorp and Ohio Valley Banc
Amazon, Bank of America and Roche are in focus as Zacks highlights growth drivers, expansion plans and product momentum across key businesses.
Zacks
News Placeholder
Top Stock Reports for Amazon, Bank of America & Roche
Amazon's AI push, sales outlook and diversified revenue streams stand out, while Bank of America and Roche navigate growth drivers and key risks.
Zacks
News Placeholder
Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg
Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into immunology and neurology.
Zacks
News Placeholder
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
BAYRY vs. RHHBY: Which Stock Is the Better Value Option?
Zacks
<
1
2
...
>

Advertisement|Remove ads.